Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
- PMID: 27118529
- DOI: 10.1177/0269881116642542
Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
Abstract
Since the wars in Iraq and Afghanistan, posttraumatic stress disorder (PTSD) has become a major area of research and development. The most widely accepted treatment for PTSD is prolonged exposure (PE) therapy, but for many patients it is intolerable or ineffective. ±3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has recently re-emerged as a new treatment option, with two clinical trials having been published and both producing promising results. However, these results have yet to be compared to existing treatments. The present paper seeks to bridge this gap in the literature. Often the statistical significance of clinical trials is overemphasized, while the magnitude of the treatment effects is overlooked. The current meta-analysis aims to provide a comparison of the cumulative effect size of the MDMA-AP studies with those of PE. Effect sizes were calculated for primary and secondary outcome measures in the MDMA-AP clinical trials and compared to those of a meta-analysis including several PE clinical trials. It was found that MDMA-AP had larger effect sizes in both clinician-observed outcomes than PE did (Hedges' g=1.17 vs. g=1.08, respectively) and patient self-report outcomes (Hedges' g=0.87 vs. g=0.77, respectively). The dropout rates of PE and MDMA-AP were also compared, revealing that MDMA-AP had a considerably lower percentage of patients dropping out than PE did. These results suggest that MDMA-AP offers a promising treatment for PTSD.
Keywords: MDMA; PTSD; meta-analysis; prolonged exposure therapy; psychotherapy.
© The Author(s) 2016.
Similar articles
-
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.Eur J Psychotraumatol. 2024;15(1):2297536. doi: 10.1080/20008066.2023.2297536. Epub 2024 Jan 4. Eur J Psychotraumatol. 2024. PMID: 38174611 Free PMC article. Clinical Trial.
-
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.Lancet Psychiatry. 2018 Jun;5(6):486-497. doi: 10.1016/S2215-0366(18)30135-4. Epub 2018 May 1. Lancet Psychiatry. 2018. PMID: 29728331 Clinical Trial.
-
Progress and promise for the MDMA drug development program.Psychopharmacology (Berl). 2018 Feb;235(2):561-571. doi: 10.1007/s00213-017-4779-2. Epub 2017 Nov 20. Psychopharmacology (Berl). 2018. PMID: 29152674 Review.
-
The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.J Psychoactive Drugs. 2015 Nov-Dec;47(5):337-44. doi: 10.1080/02791072.2015.1094156. Epub 2015 Nov 18. J Psychoactive Drugs. 2015. PMID: 26579955 Review.
-
Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.J Trauma Stress. 2020 Apr;33(2):161-170. doi: 10.1002/jts.22479. Epub 2020 Feb 19. J Trauma Stress. 2020. PMID: 32073177 Free PMC article. Clinical Trial.
Cited by
-
Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis.Neuropsychopharmacology. 2024 Jul;49(8):1208-1226. doi: 10.1038/s41386-024-01865-8. Epub 2024 Apr 23. Neuropsychopharmacology. 2024. PMID: 38654146 Free PMC article.
-
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review.Curr Neuropharmacol. 2024;22(4):557-635. doi: 10.2174/1570159X21666230428091433. Curr Neuropharmacol. 2024. PMID: 37132142 Free PMC article. Review.
-
Enhancing Psychological Interventions for Post-Traumatic Stress Disorder (PTSD) Treatment with Memory Influencing Drugs.Curr Neuropharmacol. 2023;21(3):687-707. doi: 10.2174/1570159X21666221207162750. Curr Neuropharmacol. 2023. PMID: 36503450 Free PMC article. Review.
-
Evaluating the attitudes of mental health professionals towards trials of MDMA: a randomised vignette trial.BMJ Open. 2022 Nov 25;12(11):e060360. doi: 10.1136/bmjopen-2021-060360. BMJ Open. 2022. PMID: 36428011 Free PMC article. Clinical Trial.
-
Study protocol for "MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study".Front Psychiatry. 2022 Oct 26;13:954388. doi: 10.3389/fpsyt.2022.954388. eCollection 2022. Front Psychiatry. 2022. PMID: 36386973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous